|
On September 28th, join
the Hepatitis C Support Project as it presents the Hepatitis C
Train-the-Trainer Workshop in Ft. Wayne, IN.
Who Should Attend?
Health educators, HIV/STD counselors and testers, medical
providers, substance abuse counselors, case managers, support group leaders,
corrections and law enforcement, people living with HCV and other health
professionals who will provide education, support and advocacy for people and
populations affected by HCV
After this workshop, attendees will be able to:
• Explain transmission, prevention, symptoms and treatments for
hepatitis C
• Explain basic information regarding hepatitis C
• Describe the various tests used in diagnosing hepatitis C
• Contrast between acute and chronic hepatitis C and describe
possible long-term liver damage.
• Identify various methods helpful in managing hepatitis C
• Describe current medical treatments and the side effects
• Communicate a plan of action of how to educate and support
others in your community about hepatitis C
• Learn about local resources
Please click the link below to register.
https://hcvtraining.eventbrite.com
Contact Sherika Sides at ssides@isdh.in.gov for
questions.
The Attorney General's office is pleased to announce that
registration is now open for the 8th Annual Rx Symposium. Attendees will be
provided the opportunity to network with 550 professionals from local, state,
and federal agencies, business, academia, clinicians, treatment providers,
counselors, educators, state and national leaders, and advocates impacted by Rx
drug abuse and heroin use. Tickets for the 1 ½ day program are $50 until
September 1st and thereafter $75.
Sheraton Hotel, Keystone at the Crossing,
Indianapolis, IN
October 30 - 31, 2017
CLICK HERE
TO REGISTER and view the agenda and hotel information.
Abbvie
On August 3rd, the U.S. Food and Drug Administration (FDA) approved
AbbVie's Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic
hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis. It is
the first treatment of eight weeks duration approved for all 6 major hepatitis
C virus genotypes in adult patients without cirrhosis who have not been
previously treated.
Trials including approximately 2,300 adults with genotype
1,2.3,4,5 or 6, demonstrated that 92-100 percent of patients had no virus
detected in the blood 12 weeks after completing treatment.
The wholesale acquisition cost for Mavyret is $26,400 for 8
weeks and $39,600 for 12 weeks of treatment.
Gilead
On July 18th, the FDA approved Gilead's Vosevi. The treatment
includes sofosbuvir, velpatasvir and a new drug, voxilaprevir. Vosevi treats
adults with chronic hepatitis c virus genotypes 1-6 without cirrhosis or mild
cirrhosis. It is the first treatment for approved for patients who have been
previously treated with sofosbuvir or other drugs for HCV that inhibit a
protein call NS5A.
Two trials demonstrated that 96-97 percent of patients who
received the treatment had no virus detected in the blood 12 weeks after
finishing treatment.
The wholesale acquisition cost for Vosevi is $74,760 for 12
weeks treatment.
The National Association of County and City Health Officials
(NACCHO) released its Hepatitis C Public Health Detailing kit on World
Hepatitis Day, July 28th.
Local health department efforts are critical to increasing
screening, diagnosis, and linkage to care; however, they cannot do it alone.
Partnering with healthcare providers is vital, and public health detailing is
an important strategy for increasing provider awareness and building provider
capacity to address HCV. Public health detailing uses short in-person visits
with providers to deliver key messages and essential information on treating
and preventing diseases and conditions impacting local communities.
To support local health departments to conduct provider
detailing for HCV, NACCHO developed a Hepatitis C Public Health Detailing Kit,
which is now available to download. The Detailing Kit is a collection of tools
and resources local health departments can use in implementing public health
detailing as a strategy to increase healthcare provider awareness and uptake of
effective practices for HCV screening, diagnosis, and linkage to care and
treatment.
Download the Hepatitis C Public Health Detailing Kit here:
http://www.naccho.org/programs/community-health/infectious-disease/hiv-sti/hepatitis-c/public-health-detailing-kit
Stats Explorer
Visitors to the Stats Explorer website can find information
about the prevalence of drug overdoses, sexually transmitted diseases, births
and deaths, cancer, infectious diseases and many other health issues, all in
one convenient location. Previously, the data were available through multiple
pages on the ISDH website.
Diseases and conditions provided in Stats Explorer can be viewed
as counts or rates for various time periods. Data can be displayed in a variety
of formats, including charts and maps, with the click of a button.
To use Stats Explorer, go to https://gis.in.gov/apps/isdh/statsexplorer. From the
drop-down menu, select one of many different public health categories to find
detailed data published by ISDH and other partners.
AtlasPlus
The CDC has released AtlasPlus, a tool
that gives users the ability to create tables, maps, and charts using over 15
years of HIV, viral hepatitis, STD, and TB surveillance data. AtlasPlus offers
significant upgrades from the original version of Atlas including:
- Easy, quick access to the latest data by
county, state, or U.S. total;
- 2015 data for HIV, STDs, TB and viral
hepatitis
- An upgrade to the Tables function (Based on
user feedback, we made it more intuitive to build tables based on the
exact subset of the data you want to view.);
- Improved chart capabilities such as line
graphs by year, bar charts by states or counties, pie charts for sex, bar
charts for age, race/ethnicity, transmission category (HIV), country of
birth (TB);
- New ability to create two side-by-side maps or
charts, e.g., compare two diseases, two race/ethnicity groups, or two age
groups; and
- Mobile access
Click here to visit
the page.
HepCure Toolkit
The HepCure Toolkit is a free online support resource for
hepatitis C providers and patients. The toolkit is comprised of three different
components: a weekly tele-education webinar series, provider dashboard, and a
patient app.
The Tele-Education Webinar Series is held every Tuesday from
4:30 PM - 5:30 PM EST and features many topics in hepatitis C. Continuing
education credits (CME/CNE) are offered through attendance of the webinars. All
of the webinars are archived for playback or download on HepCure's Tumblr page.
For further details, click here.
|
